Edmonton, Canada

Samuel Amedjo

This inventor holds 1 USPTO granted patent. Top assignee: Synphar Laboratories, Inc.. Active years: 1995.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 1995

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Samuel Amedjo: Innovator in Triazole Production

Introduction

Samuel Amedjo is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of chemistry, particularly in the production of triazoles. His innovative approach has led to the development of a unique process that enhances the efficiency and purity of triazole synthesis.

Latest Patents

Samuel Amedjo holds a patent for an effective process for the production of 1,2,3-triazoles. This patent describes a method where a high purity triazole is obtained through the reaction of a hydrazide and glyoxal. The process is notable for being conducted in a single pot, eliminating the need for isolating intermediates. The triazole is then isolated by distillation, and the synthesis of various N1-substituted triazoles is also detailed in the patent.

Career Highlights

Samuel Amedjo is currently employed at Synphar Laboratories, Inc., where he continues to apply his expertise in chemical synthesis. His work has not only advanced the field but has also contributed to the company's reputation for innovation in pharmaceutical chemistry.

Collaborations

Samuel has collaborated with esteemed colleagues such as Paul Spevak and Inder Pal Singh. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and enhances research outcomes.

Conclusion

Samuel Amedjo's contributions to the field of triazole production exemplify the impact of innovative thinking in chemistry. His patent and ongoing work at Synphar Laboratories, Inc. highlight his commitment to advancing scientific knowledge and practical applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…